Guardant Health

Company Overview

Guardant Health Inc. is a U.S.-based precision oncology company that develops blood and tissue tests, as well as data and AI analytics, to support cancer screening, therapy selection, and disease monitoring. It focuses on non-invasive liquid biopsy assays that analyze circulating tumor DNA, as well as tissue-based comprehensive genomic profiling tests, to identify actionable biomarkers across solid tumors.

Guardant Health generates revenue primarily from test fees paid by clinical customers (oncologists, hospitals, reference labs) and biopharmaceutical partners involved in drug development and clinical trials. Its portfolio spans the cancer care continuum from early detection and colorectal cancer screening with Shield, to therapy selection with Guardant360 tests, and minimal residual disease monitoring with Guardant Reveal, supported by a growing global footprint of laboratories and partnerships in North America, Europe, and Asia.

Financial Highlights (FY 2025)

Company's Business Segments

• Oncology : Oncology revenue includes amounts derived from the delivery of the Company's oncology tests for clinical customers, including hospitals, cancer centers, research institutions and patients, and oncology tests delivered by labs operated by the Company's strategic partners.
• Biopharma and data : Biopharma and data revenue includes amounts derived from the delivery of the Company's tests for biopharmaceutical customers, previously presented as precision oncology revenue from tests for biopharmaceutical customers.
• Screening : Screening revenue includes amounts derived from the delivery of the Company's Shield screening tests.
• Licensing and other : The Company recognizes its licensing and other revenue based on the nature and terms of the technology licensing arrangements.